Oculus Innovative Sciences to Present at the Rodman & Renshaw 12th Annual Healthcare Conference on September 14 in New York City

Published on Wednesday, 08 September 2010 08:32 Written by TradersHuddle Staff

PETALUMA, Calif.-( Business Wire )-

Oculus Innovative Sciences, Inc. (Nasdaq: OCLS), a commercial medical technology company that designs, produces and markets safe and effective tissue care products based upon the Microcyn® Technology platform, announced today it will present at the Rodman & Renshaw 12^th Annual Healthcare Conference to be held on September 13-15, 2010 at The Palace Hotel in New York City.

Hoji Alimi, Oculus’ founder and CEO, is scheduled to speak on Tuesday, September 14, 2010 at 11:40 a.m. ET (8:40 a.m. PT) in the Fahnestock Salon and will discuss the company's strategic initiatives, commercial activities, partnering activities, product pipeline and market opportunities.

Interested parties can access a live audio webcast and slide presentation at http://ir.oculusis.com/events.cfm. An archived presentation will be available on the company’s web site for 30 days.

About Oculus Innovative Sciences

Oculus Innovative Sciences is a commercial medical technology company that designs, produces and markets safe and effective tissue care products based upon the Microcyn® Technology platform, which significantly reduces the need for antibiotics while reducing infections and accelerating healing. The Microcyn Technology addresses the need for improved solutions in multiple markets including dermatology, oral care, cosmeceutical, wound care and others. It features a biocompatible, shelf-stable solution that is currently commercialized in the United States, Europe, India, China and Mexico and select Middle East countries under various country specific regulatory clearances and approvals. Several solutions derived from this platform have demonstrated, in a variety of research and investigational studies, the ability to treat a wide range of pathogens, including antibiotic-resistant strains of bacteria (including MRSA and VRE), viruses, fungi and spores; increase blood flow to the wound site; and reduce both inflammation and pain while assisting in faster wound closure. The company’s headquarters are in Petaluma, California, with manufacturing operations in the United States and Latin America. More information can be found at www.oculusis.com.

Oculus Innovative Sciences, Inc.Dan McFaddenDirector of Public and Investor Relations+1 (425) This e-mail address is being protected from spambots. You need JavaScript enabled to view it.